Placeholder Banner

Rep. Upton and DeGette Will Discuss 21st Century Cures Initiative at BIO CEO

January 8, 2015
The biotech industry answers the call for 21st Century Cures to revolutionize the drug development enterprise and ensure that patients fully realize the benefits of modern advancements in biomedical science and genomics. The 17th annual BIO CEO & Investor Conference will host U.S. Rep. Fred Upton (R - MI), Chairman of the Committee on Energy and Commerce and U.S. Rep. Diana DeGette (D - CO), Chief Deputy Whip for a fireside chat which will be moderated by Jim Greenwood, BIO President & CEO where they will discuss new approaches for expediting the discovery, development and delivery of breakthrough treatments and cures. The panel, Producing "21st Century Cures"—2015 U.S. Legislative Outlook, will take place on February 9, noon to 1 p.m. at the Waldorf Astoria in New York City.

Entrepreneurial biotech companies are at the forefront of a revolution in our understanding of the genetic and biomolecular basis of disease, and these researchers are committed to developing the next generation of modern medicines to transform patient care. However, this goal can only be realized in an environment of forward-looking public policies that sustain scientific discovery and promote biomedical advancement to save lives and reduce and eliminate suffering.

Finding new solutions today is a national imperative. Continuing an open dialogue with Chairman Upton, Congresswoman DeGette, and the members of the Energy and Commerce Committee as they seek ways to ensure our nation maintains its position as the innovation capital of the world is one step in finding these new solutions.

Now in its seventeenth year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.To learn more about the BIO CEO & Investor Conference, including registration, programming and partnering information, please visit here.

Media registration is complimentary for credentialed members of the media. All registrations are subject to verification of credentials.